Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Borderline resectable pancreatic ductal adenocarcinoma, drawn from the whole corpus: 45 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Definitions of borderline disease differ between centres, so trial populations are not comparable.
CT underestimates response after chemotherapy, and there is no validated marker to tell fibrosis from viable tumour before surgery.
Whether radiotherapy adds anything after modern chemotherapy is unresolved.
Arterial resection carries high morbidity and its benefit is unproven outside expert centres.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
Median overall survival 21.
A milestone in how this cancer is treated.
One-year overall survival 39 percent with immediate surgery against 78 percent with neoadjuvant gemcitabine plus capecitabine, 84 percent with FOLFIRINOX and 60 percent with chemoradiotherapy (p 0.
A milestone in how this cancer is treated.
18-month overall survival 66.